Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Ouabain suppresses the growth and migration abilities of glioma U‑87MG cells through inhibiting the Akt/mTOR signaling pathway and downregulating the expression of HIF‑1α.

Yang XS, Xu ZW, Yi TL, Xu RC, Li J, Zhang WB, Zhang S, Sun HT, Yu ZQ, Xu HX, Tu Y, Cheng SX.

Mol Med Rep. 2018 Apr;17(4):5595-5600. doi: 10.3892/mmr.2018.8587. Epub 2018 Feb 12.

2.

Synergistic enhancement of topotecan-induced cell death by ascorbic acid in human breast MCF-7 tumor cells.

Sinha BK, van 't Erve TJ, Kumar A, Bortner CD, Motten AG, Mason RP.

Free Radic Biol Med. 2017 Dec;113:406-412. doi: 10.1016/j.freeradbiomed.2017.10.377. Epub 2017 Oct 24.

PMID:
29079526
3.

Targeting CDK4/6 to oppose hypoxia-mediated therapeutic resistance.

Warfel NA.

Cell Cycle. 2017 Jul 3;16(13):1241-1242. doi: 10.1080/15384101.2017.1337975. Epub 2017 Jun 8. No abstract available.

PMID:
28594259
4.

The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.

Zhang J, Zhou L, Zhao S, Dicker DT, El-Deiry WS.

Cell Cycle. 2017 Jun 18;16(12):1193-1200. doi: 10.1080/15384101.2017.1320005. Epub 2017 May 9.

PMID:
28486050
5.

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy.

Yu T, Tang B, Sun X.

Yonsei Med J. 2017 May;58(3):489-496. doi: 10.3349/ymj.2017.58.3.489. Review.

6.

Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound.

Park K, Lee HE, Lee SH, Lee D, Lee T, Lee YM.

Oncotarget. 2017 Jan 31;8(5):7801-7813. doi: 10.18632/oncotarget.13955.

7.

Diacetoxyscirpenol as a new anticancer agent to target hypoxia-inducible factor 1.

Choi YJ, Shin HW, Chun YS, Leutou AS, Son BW, Park JW.

Oncotarget. 2016 Sep 20;7(38):62107-62122. doi: 10.18632/oncotarget.11529.

8.

Targeting the ROS-HIF-1-endothelin axis as a therapeutic approach for the treatment of obstructive sleep apnea-related cardiovascular complications.

Belaidi E, Morand J, Gras E, Pépin JL, Godin-Ribuot D.

Pharmacol Ther. 2016 Dec;168:1-11. doi: 10.1016/j.pharmthera.2016.07.010. Epub 2016 Aug 2. Review.

9.

Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.

Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M.

Am J Hematol. 2016 Aug;91(8):800-5. doi: 10.1002/ajh.24415. Epub 2016 Jun 25.

10.

Hypoxia-inducible factors as molecular targets for liver diseases.

Ju C, Colgan SP, Eltzschig HK.

J Mol Med (Berl). 2016 Jun;94(6):613-27. doi: 10.1007/s00109-016-1408-1. Epub 2016 Apr 20. Review.

11.

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer.

Ulivi P, Marisi G, Passardi A.

Oncotarget. 2016 Jul 19;7(29):46678-46691. doi: 10.18632/oncotarget.8712. Review.

12.

Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.

Kirkpatrick DL, Powis G.

Antioxid Redox Signal. 2017 Feb 20;26(6):262-273. doi: 10.1089/ars.2016.6633. Epub 2016 Apr 22. Review.

13.

Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling.

Hsu CW, Huang R, Khuc T, Shou D, Bullock J, Grooby S, Griffin S, Zou C, Little A, Astley H, Xia M.

Oncotarget. 2016 Feb 16;7(7):8172-83. doi: 10.18632/oncotarget.6995.

14.

HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.

Valsecchi R, Coltella N, Belloni D, Ponente M, Ten Hacken E, Scielzo C, Scarfò L, Bertilaccio MT, Brambilla P, Lenti E, Martinelli Boneschi F, Brendolan A, Ferrero E, Ferrarini M, Ghia P, Tonon G, Ponzoni M, Caligaris-Cappio F, Bernardi R.

Blood. 2016 Apr 21;127(16):1987-97. doi: 10.1182/blood-2015-07-657056. Epub 2016 Jan 29.

15.

Intravitreal Topotecan Inhibits Laser-induced Choroidal Neovascularization in a Rat Model.

Gholipour MA, Kanavi MR, Ahmadieh H, Aldavood SJ, Nourinia R, Hosseini SB, Daftarian N, Nashtaei EM, Tousi A, Safi S.

J Ophthalmic Vis Res. 2015 Jul-Sep;10(3):295-302. doi: 10.4103/2008-322X.170339.

16.

Interleukin-1β Affects MDAMB231 Breast Cancer Cell Migration under Hypoxia: Role of HIF-1α and NFκB Transcription Factors.

Filippi I, Carraro F, Naldini A.

Mediators Inflamm. 2015;2015:789414. doi: 10.1155/2015/789414. Epub 2015 Nov 30.

17.

Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy.

Weijer R, Broekgaarden M, Krekorian M, Alles LK, van Wijk AC, Mackaaij C, Verheij J, van der Wal AC, van Gulik TM, Storm G, Heger M.

Oncotarget. 2016 Jan 19;7(3):3341-56. doi: 10.18632/oncotarget.6490.

18.

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.

Taschner-Mandl S, Schwarz M, Blaha J, Kauer M, Kromp F, Frank N, Rifatbegovic F, Weiss T, Ladenstein R, Hohenegger M, Ambros IM, Ambros PF.

Oncotarget. 2016 Jan 19;7(3):3571-86. doi: 10.18632/oncotarget.6527.

19.

HIF-1α pathway: role, regulation and intervention for cancer therapy.

Masoud GN, Li W.

Acta Pharm Sin B. 2015 Sep;5(5):378-89. doi: 10.1016/j.apsb.2015.05.007. Epub 2015 Jun 6. Review.

20.

Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.

Lin D, Wu J.

World J Gastroenterol. 2015 Nov 14;21(42):12171-8. doi: 10.3748/wjg.v21.i42.12171. Review.

Supplemental Content

Support Center